PepGen Inc. (NASDAQ:PEPG – Get Free Report) was the recipient of a significant growth in short interest in February. As of February 15th, there was short interest totalling 852,600 shares, a growth of 26.2% from the January 31st total of 675,600 shares. Based on an average daily volume of 2,050,000 shares, the short-interest ratio is currently 0.4 days. Approximately 3.1% of the company’s stock are short sold.
Wall Street Analysts Forecast Growth
Several equities research analysts recently weighed in on the company. Bank of America lowered PepGen from a “neutral” rating to an “underperform” rating and set a $3.00 target price for the company. in a report on Monday, December 16th. HC Wainwright reiterated a “buy” rating and set a $16.00 target price on shares of PepGen in a research note on Monday, February 24th. Finally, Wedbush decreased their price target on shares of PepGen from $19.00 to $12.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th.
Check Out Our Latest Analysis on PEPG
Institutional Inflows and Outflows
PepGen Trading Down 10.2 %
PepGen stock traded down $0.27 during mid-day trading on Thursday, hitting $2.37. The stock had a trading volume of 584,136 shares, compared to its average volume of 774,048. PepGen has a 12 month low of $1.16 and a 12 month high of $19.30. The stock has a 50-day simple moving average of $2.28 and a two-hundred day simple moving average of $5.54. The stock has a market capitalization of $77.48 million, a PE ratio of -0.80 and a beta of 1.53.
PepGen (NASDAQ:PEPG – Get Free Report) last released its quarterly earnings results on Monday, February 24th. The company reported ($0.68) earnings per share for the quarter, beating the consensus estimate of ($0.81) by $0.13. Sell-side analysts expect that PepGen will post -2.73 earnings per share for the current fiscal year.
PepGen Company Profile
PepGen Inc, a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients.
Further Reading
- Five stocks we like better than PepGen
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
- Investing in Travel Stocks Benefits
- Taiwan Semi’s $100 Billion Investment: Fate of the Chipmakers
Receive News & Ratings for PepGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PepGen and related companies with MarketBeat.com's FREE daily email newsletter.